Compare ARK Next Generation Internet ETF (ARKW) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Next Generation Internet ETF vs BridgeBio Pharma Inc — how do they compare? ARK Next Generation Internet ETF trades at $147, while BridgeBio Pharma Inc trades at $85.01 (market cap $16.81B). The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | BBIO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $90.17 |
52-Week Low | $114.45 | $44.81 |
Market Cap | — | $16.81B |
Enterprise Value | — | $18.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $148.42, down 0.75% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 52.51 suggesting balanced buying pressure. Support levels are established at $144 and $142, while resistance sits at $147 and $148. Recent news highlights Cathie Wood's continued focus on innovative technology investments through her ETF strategies.
The ETF's exposure to disruptive innovation themes presents growth potential amid technology sector momentum. Key risks include concentration in high-growth tech stocks and market volatility sensitivity. Institutional interest remains strong given ARK Invest's track record in identifying transformative technologies.
BridgeBio Pharma (BBIO) trades at $85.89, down 4.75% today but remains near 52-week highs following positive clinical news. The stock shows strong technical momentum with bullish moving averages and support at $85. Fundamentally, revenue grew to $502M in 2025 but net losses widened to -$725M with negative cash flow from operations. Recent news highlights competitor setbacks boosting confidence in Attruby and a $1B preferred equity raise to fund launches.
Outlook hinges on successful drug launches and pipeline execution, with analyst consensus bullish (92% buy ratings) and a $103 price target. Key risks include sustained cash burn, clinical trial outcomes, and high valuation (P/S 28.5) pricing in future success. The stock offers growth potential but requires monitoring of profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
